Table 2. Estimated distribution of persons with and persons without a diagnosis of AIDS within 12 months of diagnosis of HIV infection, by selected characteristics, 2001—30 areas with confidential name-based HIV infection reporting
~~ Male-to-male sexual contact and injection drug
use
554
58
394
42
948
100
~~ Heterosexual contact
1,858
58
1,333
42
3,191
100
~~ Otherb
81
48
87
52
167
100
Subtotal
10,373
58
7,621
42
17,994
100
Female
adult or adolescent
~~ Injection drug use
948
64
533
36
1,481
100
~~ Heterosexual contact
3,974
68
1,852
32
5,826
100
~~ Otherb
65
48
70
52
136
100
Subtotal
4,987
67
2,455
33
7,442
100
Child
(<13 yrs at diagnosis)
~~ Perinatal
148
77
44
23
192
100
~~ Otherc
12
83
2
17
14
100
Subtotal
160
77
47
23
206
100
Totald
15,520
61
10,123
39
25,642
100
Note. These numbers do not represent actual cases in persons with a diagnosis of HIV infection or AIDS. Rather, these numbers are point estimates of cases diagnosed that have been adjusted for reporting delays and for redistribution of cases in persons initially reported without an identified risk. The estimates have not been adjusted for incomplete reporting.
Data include persons in whom AIDS has developed and persons whose first diagnosis of HIV infection and the diagnosis of AIDS were made at the same time.
Data exclude 1 person whose month of diagnosis of HIV infection is unknown.
Since 1998, the following 30 areas have had laws or regulations requiring confidential name-based HIV infection reporting: Alabama, Arizona, Arkansas, Colorado, Florida, Idaho, Indiana, Iowa, Louisiana, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Jersey, New Mexico, North Carolina, North Dakota, Ohio, Oklahoma, South Carolina, South Dakota, Tennessee, Utah, Virginia, West Virginia, Wisconsin, Wyoming, and the U.S. Virgin Islands. Since July 1997, Florida has had confidential name-based HIV infection reporting only for new diagnoses.
a
Percentages represent proportions of the total number of diagnoses of HIV/AIDS made during 2001 for the corresponding group (see row entries).
b
Includes hemophilia, blood transfusion, perinatal, and risk not reported or not identified.
c
Includes hemophilia, blood transfusion, and risk not reported or not identified.
d
Includes 220 persons of unknown or multiple race. Because column totals were calculated independently of the values for the subpopulations, the values in each column may not sum to the column total.
